Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorAbbVie

About this trial

This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.

Eligibility criteria

Qualifiers

BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.

A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.

Disqualifiers

History: of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic, neurologic, or psychiatric disease or disorder, history of Raynaud's Phenomenon, or any uncontrolled medical illness.

History of any clinically significant sensitivity or allergy to any medication or food.

Trial design

Treatments tested in this trial

  • Ubrogepant
  • Ubrogepant

Treatment groups

52 Participants
are divided into 4 treatment groups

Locations

This trial has no locations

Sponsors and collaborators